Resistance in oncolytic viral therapy for solid tumors

被引:0
|
作者
Ambegoda-Liyanage, Prathibha [1 ]
Jang, Sophia R. -J. [1 ]
机构
[1] Texas Tech Univ, Dept Math & Stat, Lubbock, TX 79407 USA
关键词
Oncolytic viral therapy; Resistance; Volterra-Lyapunov stability; Hopf bifurcation; MATHEMATICAL-MODEL; DRUG-RESISTANCE; VIROTHERAPY; STABILITY; BACTERIA;
D O I
10.1016/j.amc.2024.128546
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
Therapeutic resistance poses a significant obstacle in cancer control, and oncolytic viral therapy also faces the challenge of virus resistance. In this study, we propose models based on ordinary and delay differential equations to investigate the impact of resistance on tumor -virus interactions. The tumor cells are categorized as sensitive, resistant, or infected by oncolytic viruses. We show that if resistant tumor cells cannot be transformed into sensitive cells, every tumor cell will eventually acquire resistance. The model can possess at most one positive equilibrium, and we determine the critical delay magnitude beyond which the equilibrium becomes unstable. Our numerical simulations indicate that delays in the viral cycle can result in an increase in the total tumor burden. However, in terms of the overall tumor load, resistance may not be detrimental to the host if the delay in the viral cycle is substantial.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] RAIDDing ER Stress for Oncolytic Viral Therapy
    McConkey, David J.
    CANCER CELL, 2011, 20 (04) : 416 - 418
  • [32] Clinical development directions in oncolytic viral therapy
    Eager, R. M.
    Nemunaitis, J.
    CANCER GENE THERAPY, 2011, 18 (05) : 305 - 317
  • [33] Impact of tumor microenvironment on oncolytic viral therapy
    Wojton, Jeffrey
    Kaur, Balveen
    CYTOKINE & GROWTH FACTOR REVIEWS, 2010, 21 (2-3) : 127 - 134
  • [34] Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research
    Lou, E
    ANNALS OF MEDICINE, 2004, 36 (01) : 2 - 8
  • [35] Evolution of anti-viral and anti-tumor immunity in tumors in response to oncolytic virus therapy
    Lyudovyk, Olga
    Burman, Bharat
    Ceglia, Nicholas
    Greenbaum, Benjamin
    Elhanati, Yuval
    Zamarin, Dmitriy
    CANCER RESEARCH, 2024, 84 (07)
  • [36] Oncolytic viruses for genetic therapy of gastrointestinal tumors
    Bitzer, M
    Lauer, UM
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (07): : 667 - 674
  • [37] CEA-regulated Oncolytic Virus Anticancer Therapy: A Promising Strategy for Rare Solid Tumors
    Yang, Yuqi
    Wang, Shuhang
    Ma, Peiwen
    Tang, Qiyu
    Li, Yandong
    Fang, Yuan
    Zhu, Qi
    Tao, Wei
    Zha, Yan
    Li, Ning
    CURRENT CANCER DRUG TARGETS, 2022, 22 (02) : 126 - 132
  • [38] Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option
    He, Jiasen
    Munir, Faryal
    Ragoonanan, Dristhi
    Zaky, Wafik
    Khazal, Sajad J.
    Tewari, Priti
    Fueyo, Juan
    Gomez-Manzano, Candelaria
    Jiang, Hong
    IMMUNO, 2023, 3 (01): : 37 - 56
  • [39] Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
    Cervera-Carrascon, Victor
    Quixabeira, Dafne C. A.
    Havunen, Riikka
    Santos, Joao M.
    Kutvonen, Emma
    Clubb, James H. A.
    Siurala, Mikko
    Heini, Camilla
    Zafar, Sadia
    Koivula, Teija
    Lumen, Dave
    Vaha, Marjo
    Garcia-Horsman, Arturo
    Airaksinen, Anu J.
    Sorsa, Suvi
    Anttila, Marjukka
    Hukkanen, Veijo
    Kanerva, Anna
    Hemminki, Akseli
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 17 : 47 - 60
  • [40] Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
    Zhao, Xianda
    Subramanian, Subbaya
    CANCER RESEARCH, 2017, 77 (04) : 817 - 822